Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer

Figure 2

(a) Difference between LS mean change from baseline in FACT-P total scores in apalutamide plus ADT and ADT monotherapy groups. LS mean difference <0 favors ADT. (b) Difference between LS mean change from baseline in FACT-P total scores between apalutamide monotherapy and ADT monotherapy groups. LS mean difference <0 favors ADT. (c) Median time to PSA progression. (d) Median time to serum testosterone (T) recovery (T > 150 ng/dL). (e) Mean T levels over time.

(a)

(b)

(c)

(d)

(e)